RxDoctor Payments Data

Jennifer Rein, MD

Family Medicine · Hanover, PANPI 1376542159

Payments from drug & device makers

$8,750in general payments, 2019–2025

Across 622 payments — averaging $14.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Pfizer$910
  • GSK$755
  • Lilly USA, LLC$531
  • AstraZeneca$425
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$8,63699%
  • Education$1141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,750 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$324,996
Medicare patients
298
Services billed
9,661

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban96$135,822
OzempicSemaglutide36$62,862
Soliqua 100-33Insulin Glargine/Lixisenatide52$51,006
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$50,450
NuplazidPimavanserin Tartrate12$49,302
JardianceEmpagliflozin39$34,969
MounjaroTirzepatide30$34,148
MyrbetriqMirabegron40$29,940
RybelsusSemaglutide22$27,399
CreonLipase/Protease/Amylase13$26,073
XareltoRivaroxaban18$22,814
Janumet XrSitagliptin Phos/Metformin Hcl22$21,315
JanuviaSitagliptin Phosphate23$18,329
TrulicityDulaglutide11$14,130
Jentadueto XrLinagliptin/Metformin Hcl17$8,438

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$910$135,82296 claims
Novo NordiskOzempic, Rybelsus$1,085$90,26058 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$114$51,00652 claims
GSKTrelegy Ellipta$755$50,45053 claims
Lilly USA, LLCMounjaro, Trulicity$531$48,27841 claims
Boehringer IngelheimJardiance, Jentadueto Xr$248$43,40756 claims
MerckJanumet Xr, Januvia$284$39,64345 claims
Astellas Pharma US IncMyrbetriq$166$29,94040 claims
AbbVieCreon, Synthroid$1,682$27,97247 claims
Johnson & JohnsonXarelto$74$22,81418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Hanover

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →